Total Payments
$5,179
2024 Payments
$633.96
Companies
33
Transactions
269
Medicare Patients
9,835
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$4,404 (85.0%)
Travel$655.28 (12.7%)
Education$119.98 (2.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,404 | 261 | 85.0% |
| Travel and Lodging | $655.28 | 5 | 12.7% |
| Education | $119.98 | 3 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Edwards Lifesciences Corporation | $872.30 | 10 | $0 (2019) |
| GlaxoSmithKline, LLC. | $863.10 | 80 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $563.94 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $432.79 | 22 | $0 (2024) |
| Insmed, Inc. | $368.88 | 14 | $0 (2024) |
| Gilead Sciences, Inc. | $347.51 | 17 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $222.98 | 17 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $215.01 | 13 | $0 (2024) |
| United Therapeutics Corporation | $187.05 | 6 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $118.83 | 15 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $633.96 | 34 | GlaxoSmithKline, LLC. ($160.49) |
| 2023 | $541.82 | 22 | Actelion Pharmaceuticals US, Inc. ($132.42) |
| 2022 | $308.77 | 15 | Insmed, Inc. ($90.18) |
| 2021 | $431.01 | 22 | Actelion Pharmaceuticals US, Inc. ($97.68) |
| 2020 | $276.63 | 16 | Actelion Pharmaceuticals US, Inc. ($108.06) |
| 2019 | $1,463 | 51 | Edwards Lifesciences Corporation ($872.30) |
| 2018 | $577.43 | 40 | GlaxoSmithKline, LLC. ($193.24) |
| 2017 | $946.52 | 69 | Gilead Sciences Inc ($203.98) |
All Payment Transactions
269 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.22 | General |
| 12/12/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 12/12/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $1.36 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Respiratory | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $0.71 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $31.26 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/29/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.26 | General |
| 10/14/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Respiratory | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: RESPIRATORY | ||||||
| 08/13/2024 | United Therapeutics Corporation | REMODULIN (Drug), ORENITRAM | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.24 | General |
| 05/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: RESPIRATORY | ||||||
| 05/15/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: RESPIRATORY | ||||||
| 04/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,496 | 3,283 | $781,970 | $315,693 |
| 2022 | 20 | 2,570 | 3,386 | $818,190 | $324,329 |
| 2021 | 23 | 2,527 | 3,368 | $754,838 | $303,880 |
| 2020 | 23 | 2,242 | 3,260 | $685,294 | $271,895 |
Total Patients
9,835
Total Services
13,297
Medicare Billing
$1.2M
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 341 | 574 | $262,318 | $100,009 | 38.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 413 | 672 | $141,792 | $64,705 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 411 | 623 | $133,322 | $59,371 | 44.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 182 | 184 | $75,624 | $25,839 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 206 | 219 | $31,755 | $14,156 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $26,596 | $10,419 | 39.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 73 | $21,170 | $10,081 | 47.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 103 | $15,038 | $6,598 | 43.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 134 | 136 | $14,552 | $5,583 | 38.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 126 | 128 | $15,360 | $3,517 | 22.9% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 106 | 107 | $11,984 | $2,821 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,672 | $2,650 | 39.7% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 74 | 75 | $6,225 | $2,505 | 40.2% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 57 | 57 | $5,928 | $2,326 | 39.2% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 16 | 17 | $3,893 | $1,492 | 38.3% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 30 | 60 | $3,720 | $1,473 | 39.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $3,336 | $1,268 | 38.0% |
| 88738 | Hemoglobin measurement | Office | 2023 | 134 | 136 | $1,904 | $669.12 | 35.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 11 | 11 | $781.00 | $210.00 | 26.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 324 | 645 | $294,765 | $114,954 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 424 | 562 | $120,268 | $52,204 | 43.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 351 | 627 | $132,297 | $51,551 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 150 | 154 | $63,294 | $24,370 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 259 | 281 | $40,745 | $18,873 | 46.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 63 | 81 | $23,490 | $10,892 | 46.4% |
About Dr. Kisha Morgan, MD
Dr. Kisha Morgan, MD is a Pulmonary Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427080910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kisha Morgan, MD has received a total of $5,179 in payments from pharmaceutical and medical device companies, with $633.96 received in 2024. These payments were reported across 269 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($4,404).
As a Medicare-enrolled provider, Morgan has provided services to 9,835 Medicare beneficiaries, totaling 13,297 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Sarasota, FL
- Active Since 07/07/2006
- Last Updated 01/21/2022
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427080910
Products in Payments
- TRELEGY ELLIPTA (Drug) $373.15
- Arikayce (Drug) $368.88
- OPSUMIT (Drug) $264.30
- Adempas (Drug) $222.98
- NUCALA (Biological) $211.14
- UPTRAVI (Drug) $210.76
- OFEV (Drug) $204.06
- ANORO (Drug) $156.34
- ORENITRAM (Drug) $139.20
- XARELTO (Drug) $98.77
- Letairis (Drug) $94.55
- GLASSIA (Biological) $82.46
- UTIBRON (Drug) $75.26
- TEZSPIRE (Biological) $70.57
- BREO (Drug) $66.83
- Fetroja (Drug) $62.23
- INCRUSE (Drug) $55.64
- OPSUMIT MACITENTAN (Drug) $53.85
- Pulmonx Endobronchial Valve EBV (Device) $50.00
- DUPIXENT (Biological) $49.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Sarasota
Ryan Dunn, M.d, M.D
Pulmonary Disease — Payments: $42,879
Pulmonary Disease $42,879
Dr. Darren Hoffberger, D.o, D.O
Pulmonary Disease — Payments: $11,749
Pulmonary Disease $11,749
Mr. Gregory Ferreira, Md, MD
Pulmonary Disease — Payments: $9,953
Pulmonary Disease $9,953
Rabih Loutfi, Md, MD
Pulmonary Disease — Payments: $9,068
Pulmonary Disease $9,068
Dr. Todd Horiuchi, Md, MD
Pulmonary Disease — Payments: $6,301
Pulmonary Disease $6,301
Craig Harcup, M.d, M.D
Pulmonary Disease — Payments: $5,573
Pulmonary Disease $5,573